←
Floor Backes85 posts
Floor Backes avatar

Floor Backes

@FBackesMD

Gynecologic oncologist at the James Cancer Hospital at the Ohio State University, clinical trials to improve patients lives. my opinions not OSU’s.

◷ Joined January 2019▧ 49 Photos and videos
Floor Backes avatar
Floor Backes@FBackesMD·16 Sep 2024

Drs. Colombo and Ray-Coquard share their thoughts on frontline PARP inhibitor maintenance for ovarian cancer and differences in overall survival and bevacizumab use . Is it study population, the drug, the combination, duration of treatment? #ESMO2024 @myESMO @SGO_org

Post attachmentPost attachmentPost attachment
Floor Backes avatar
Floor Backes@FBackesMD·15 Sep 2024

Exciting new options on the horizon for patients with recurrent ovarian, endometrial and cervical cancer : 3 Trop2 targeting ADCs were presented #ESMO2024 with relatively similar response rates (30-40%) and DOR > 6 months.

Post attachmentPost attachmentPost attachmentPost attachment
Floor Backes avatar
Floor Backes@FBackesMD·15 Sep 2024

We have not been able to improve outcomes of PARP inhibitor maintenance in the second line. ICON9 shows no benefit of maintenance olaparib and cediranib over olaparib alone in platinum sensitive recurrent ovarian cancer and increased toxicity @myESMO @SGO_org #ESMO2024 #ESMO24

Post attachment
Floor Backes avatar
Floor Backes@FBackesMD·14 Sep 2024

Again no benefit of immunotherapy in ovarian cancer . the addition of nivolumab to rucaparib as maintenance therapy for front line ovarian cancer did not results in better survival and increased toxicity. @myESMO @SGO_org #ESMO24

Post attachmentPost attachment
Floor Backes avatar
Floor Backes@FBackesMD·14 Sep 2024

no OS benefit with niraparib first line maintenance therapy, but survival almost 70 months in HRD! I’m so relieved: no detrimental effect on OS and significant PFS benefit. 3x higher post progression PARPi use may have contributed to lack of OS benefit. @myESMO @SGO_org #ESMO24

Post attachmentPost attachment
Floor Backes avatar
Floor Backes@FBackesMD·14 Sep 2024

“The most exciting negative study” ! While there was no benefit of pembro added to adjuvant chemotherapy in endometrial cancer, in dMMR pembro decreased the risk of recurrence or death but 70% (HR 0.3) ⁦@myESMO⁩ ⁦@SGO_org⁩ #esmo2024

Post attachment